Last reviewed · How we verify
Drug: Apixaban sprinkle capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Drug: Apixaban sprinkle capsules (Drug: Apixaban sprinkle capsules) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Drug: Apixaban sprinkle capsules TARGET | Drug: Apixaban sprinkle capsules | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Drug: Apixaban sprinkle capsules CI watch — RSS
- Drug: Apixaban sprinkle capsules CI watch — Atom
- Drug: Apixaban sprinkle capsules CI watch — JSON
- Drug: Apixaban sprinkle capsules alone — RSS
Cite this brief
Drug Landscape (2026). Drug: Apixaban sprinkle capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-apixaban-sprinkle-capsules. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab